For decades, the treatment of obstructive hypertrophic cardiomyopathy (oHCM) was limited to managing symptoms and preventing complications, with no cure in sight. That paradigm is shifting rapidly. The landscape of cardiac care is evolving from reactive management to targeted intervention, driven by the recent approval of the first drugs that address the disease’s underlying mechanics.
With the 2022 approval of mavacamten (Camzyos) and the subsequent approval of aficamten (Myqorzo) in December 2025, clinicians now have precise tools to calm the overactive heart muscle. These advancements signal a hopeful period for patients, offering a pipeline of therapies that promise not just relief, but potentially transformative improvements in quality of life.
The Rise of Cardiac Myosin Inhibitors
The cornerstone of this new era is the class of drugs known as cardiac myosin inhibitors. Both mavacamten and aficamten function by modulating the interaction between actin and myosin—the primary proteins responsible for muscle contraction. By slowing this interaction, these medications prevent the heart muscle from squeezing too forcefully, allowing for a more normal, efficient contraction.
“You just get a more normal contraction,” explains Anjali Tiku Owens, MD, medical director of the Center for Inherited Cardiac Disease at Penn Medicine.
Clinical data indicates that both drugs are roughly equally effective in reducing hallmark symptoms such as shortness of breath and chest pain. This dual availability provides physicians with flexibility in prescribing, depending on individual patient profiles and insurance coverage.
The pipeline for this class remains active. Delocamten, a third-generation myosin inhibitor currently in Phase 2 clinical trials, is being designed to offer a more flexible dosing schedule. If successful, it could address adherence challenges associated with current treatments.
Expanding the Pharmacological Arsenal
While myosin inhibitors target the mechanics of contraction, other drug classes are being investigated for their metabolic and structural benefits.
SGLT2 Inhibitors
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as sotagliflozin, have revolutionized the treatment of heart failure and diabetes. Researchers are now exploring their efficacy in oHCM. These drugs work by removing excess sugar from the body, a process that appears to confer beneficial effects on cardiac function, although the exact mechanism in HCM remains under investigation.
A pivotal Phase 3 trial for sotagliflozin is expected to conclude in August 2026. If the results are positive, regulatory approval could follow within months, adding a widely accessible, oral medication to the oHCM toolkit.
Sarcomere Modulators
While myosin inhibitors help the heart squeeze effectively, sarcomere modulators aim to improve how the heart fills with blood. “It basically acts to improve the heart muscle’s relaxation phase,” says Sara Saberi, MD, an assistant professor in cardiovascular medicine at the University of Michigan.
The investigational drug EDG-7500 is currently in Phase 2 trials, showing promising results for both safety and improved heart function. If Phase 3 trials maintain this trajectory, FDA approval could be possible around 2030, offering a complementary approach to current therapies.
Less-Invasive Surgical Alternatives
Surgery remains necessary for some patients, particularly those who do not respond adequately to medication. However, the approach to surgical intervention is becoming less invasive and lower risk.
Traditional septal myectomy requires open-heart surgery, involving a sternotomy (cracking the breastbone). Two emerging techniques aim to reduce this burden:
- Transapical Beating-Heart Septal Myectomy: This procedure involves a much smaller incision and does not require stopping the heart or breaking the breastbone. Early clinical trials in China have demonstrated safety and efficacy, paving the way for potential U.S. approval.
- Minimally Invasive Electro Septal Myectomy: Described by Dr. Saberi as working “sort of like an apple corer,” this technique allows surgeons to precisely target and remove specific amounts of thickened heart muscle through a small incision. Small studies have already shown this method to be safe and effective.
These innovations promise reduced recovery times and lower surgical risks, making intervention more accessible to patients who might previously have been deemed too high-risk for traditional surgery.
The Long-Term Promise of Gene Therapy
Looking further ahead, gene therapy offers the potential for a true cure. Scientists have identified nearly 30 genes linked to HCM, most of which influence heart muscle contraction. Technologies like CRISPR could theoretically silence faulty genes or replace them with healthy ones, correcting the root cause of the disease.
However, this field is in its infancy. “We’re at the very beginning with gene therapy, with the first few patients participating in Phase I clinical trials,” notes Dr. Owens. Significant research and regulatory hurdles remain before gene editing becomes a standard clinical option.
Accessing Cutting-Edge Treatments
For patients whose symptoms are not fully controlled by approved therapies like mavacamten or aficamten, clinical trials offer a pathway to access these emerging treatments. Patients are encouraged to:
- Research ongoing studies at ClinicalTrials.gov.
- Consult with their cardiologist to determine eligibility for specific trials.
- Stay informed about new approvals and guideline updates.
Conclusion
The treatment of obstructive hypertrophic cardiomyopathy is undergoing a profound transformation. With the establishment of cardiac myosin inhibitors as a standard of care, the emergence of metabolic and relaxation-targeting drugs, and the development of minimally invasive surgical techniques, patients now have more options than ever before. While gene therapy remains a long-term horizon, the immediate future of oHCM care is defined by precision, efficacy, and improved quality of life.
